484 biotech investors
We list 484 biotech investors as of November 2026: 302 have an SEC filing on file and 182 were checked on the firm's own website or an official register, and the list was last checked on 9 Nov 2026. The states with the most are California (108), Massachusetts (37) and New York (29).
Top 10 biotech investors, ranked by recent fund activity
Among firms with a published profile and a dated fund or deal in the last 24 months. The rule: Activity score out of 100: recency of the latest fund filing or dated deal (40: within 3 months 40, 6 months 30, 12 months 20, 24 months 10), share of the observed portfolio in this sector (30; 15 when the sector is stated only), size of the fund on file on a log scale (20) and completeness of the public record (10). It is a measure of activity and fit, not of quality or returns. The same rule orders the whole list; it is repeated in the method box.
Cambridge Innovation Capital
Type: VC firm · HQ: Cambridge, United Kingdom · Stages: Seed, Series A, Growth · Focus: Biotech, Healthtech, AI, Fintech · Latest activity: New fund, Oct 2026 · Fund size or assets: £600M (own site)
Latest fund filing dated Oct 2026; £600M on file (own site); 53% of its observed portfolio is biotech and life sciences; 8 named decision-makers on file.
Vida Ventures
Type: VC firm · HQ: Los Angeles, CA · Focus: Biotech, Healthtech · Latest activity: New fund, Sep 2026 · Fund size on file: $750M (SEC Form D, 2021)
Latest fund filing dated Sep 2026; $750M fund on file (SEC Form D, 2021); 100% of its observed portfolio is biotech and life sciences; 8 named decision-makers on file.
ARCH Venture Partners
Type: VC firm · HQ: Chicago, IL · Stages: Pre-seed, Seed · Focus: Biotech, Healthtech, Deep Tech · Latest activity: New fund, Aug 2026 · Fund size on file: $3.0B (SEC Form D, 2024)
Latest fund filing dated Aug 2026; $3.0B fund on file (SEC Form D, 2024); 81% of its observed portfolio is biotech and life sciences; 8 named decision-makers on file.
TCGX
Type: VC firm · HQ: Palo Alto, CA · Focus: Biotech, Healthtech · Latest activity: New fund, Oct 2026 · Fund size on file: $600M (SEC Form D, 2026)
Latest fund filing dated Oct 2026; $600M fund on file (SEC Form D, 2026); 96% of its observed portfolio is biotech and life sciences; 8 named decision-makers on file.
SR One
Type: VC firm · HQ: Wayne, PA · Focus: Biotech, Healthtech · Latest activity: New fund, Sep 2026 · Fund size on file: $600M (SEC Form D, 2024)
Latest fund filing dated Sep 2026; $600M fund on file (SEC Form D, 2024); 100% of its observed portfolio is biotech and life sciences; 8 named decision-makers on file.
Hatteras Venture Partners
Type: VC firm · HQ: Durham, NC · Stages: Seed · Focus: Biotech, Healthtech, Medtech · Latest activity: New fund, Oct 2026 · Fund size on file: $250M (SEC Form D, 2023)
Latest fund filing dated Oct 2026; $250M fund on file (SEC Form D, 2023); 62% of its observed portfolio is biotech and life sciences; 8 named decision-makers on file.
Thirdrockventures
Type: VC firm · HQ: Boston, MA · Stages: Pre-seed, Seed · Focus: Biotech, Healthtech, Medtech · Latest activity: New fund, Jun 2026 · Fund size on file: $1.1B (SEC Form D, 2022)
Latest fund filing dated Jun 2026; $1.1B fund on file (SEC Form D, 2022); 94% of its observed portfolio is biotech and life sciences; 8 named decision-makers on file.
First In Ventures
Type: VC firm · HQ: Hobe Sound, FL · Stages: Pre-seed, Seed · Focus: Biotech, Healthtech, AI, Climate Tech · Latest activity: New fund, Sep 2026 · Fund size on file: $22M (SEC Form D, 2026)
Latest fund filing dated Sep 2026; $22M fund on file (SEC Form D, 2026); 69% of its observed portfolio is biotech and life sciences; 5 named decision-makers on file.
M Ventures
Type: Corporate VC · HQ: Amsterdam, Netherlands · Focus: Biotech, Healthtech, AI, Deep Tech · Latest activity: Portfolio news, Oct 2026 · Private fund assets: $27M (SEC Form ADV)
Portfolio news dated Oct 2026; $27M on file (SEC Form ADV); 92% of its observed portfolio is biotech and life sciences; 8 named decision-makers on file.
AMR Action Fund
Type: VC firm · HQ: Boston, MA · Focus: Biotech, Healthtech, Media, Medtech · Latest activity: Portfolio news, Aug 2026 · Private fund assets: $977M (SEC Form ADV)
Portfolio news dated Aug 2026; $977M on file (SEC Form ADV); 82% of its observed portfolio is biotech and life sciences; 1 named decision-maker on file.
First 25 of 484 biotech investors
| Investor | Type | HQ | Stagesour research | Focusour research | Latest fund or deal | Fund sizeas filed or stated | Checked | Contacts |
|---|---|---|---|---|---|---|---|---|
| Cambridge Innovation Capital | VC firm | Cambridge, United Kingdom | Seed, Series A, Growth | Biotech, Healthtech, AI, Fintech | New fund, Oct 2026 | £600M (own site) | 4 Nov 2026 | 8 names, firm email · Unlock |
| Vida Ventures | VC firm | Los Angeles, CA | Biotech, Healthtech | New fund, Sep 2026 | $750M (SEC Form D, 2021) | 4 Nov 2026 | 8 names, firm email · Unlock | |
| ARCH Venture Partners | VC firm | Chicago, IL | Pre-seed, Seed | Biotech, Healthtech, Deep Tech | New fund, Aug 2026 | $3.0B (SEC Form D, 2024) | 4 Nov 2026 | 8 names · Unlock |
| TCGX | VC firm | Palo Alto, CA | Biotech, Healthtech | New fund, Oct 2026 | $600M (SEC Form D, 2026) | 4 Nov 2026 | 8 names, firm email · Unlock | |
| SR One | VC firm | Wayne, PA | Biotech, Healthtech | New fund, Sep 2026 | $600M (SEC Form D, 2024) | 4 Nov 2026 | 8 names · Unlock | |
| Hatteras Venture Partners | VC firm | Durham, NC | Seed | Biotech, Healthtech, Medtech | New fund, Oct 2026 | $250M (SEC Form D, 2023) | 4 Nov 2026 | 8 names · Unlock |
| Thirdrockventures | VC firm | Boston, MA | Pre-seed, Seed | Biotech, Healthtech, Medtech | New fund, Jun 2026 | $1.1B (SEC Form D, 2022) | 4 Nov 2026 | 8 names · Unlock |
| First In Ventures | VC firm | Hobe Sound, FL | Pre-seed, Seed | Biotech, Healthtech, AI, Climate Tech | New fund, Sep 2026 | $22M (SEC Form D, 2026) | 4 Nov 2026 | 5 names, firm email · Unlock |
| M Ventures | Corporate VC | Amsterdam, Netherlands | Biotech, Healthtech, AI, Deep Tech | Portfolio news, Oct 2026 | $27M (SEC Form ADV) | 4 Nov 2026 | 8 names, firm email · Unlock | |
| AMR Action Fund | VC firm | Boston, MA | Biotech, Healthtech, Media, Medtech | Portfolio news, Aug 2026 | $977M (SEC Form ADV) | 5 Nov 2026 | 1 name · Unlock | |
| Lionheart Ventures | VC firm | San Francisco, CA | Biotech, Healthtech, Climate Tech, AI | New fund, Aug 2026 | $21M (SEC Form D, 2021) | 4 Nov 2026 | 8 names, firm email · Unlock | |
| Longitude Venture Partners | VC firm | Menlo Park, CA | Growth | Biotech, Healthtech, Medtech | New deal, Jun 2026 | $600M (SEC Form D, 2022) | 5 Nov 2026 | 8 names · Unlock |
| Sofinnova | VC firm | Menlo Park, CA | Biotech, Healthtech | New fund, Jun 2026 | $550M (SEC Form D, 2024) | 4 Nov 2026 | 8 names, firm email · Unlock | |
| Future Ventures | VC firm | Los Altos, CA | Seed | Biotech, Healthtech, AI, Energy | New fund, Oct 2026 | $200M (SEC Form D, 2021) | 4 Nov 2026 | 4 names · Unlock |
| Claret Capital Partners | Venture debt | London, United Kingdom | Series B, Growth, Late stage | Biotech, Healthtech, Climate Tech, SaaS | New deal, Oct 2026 | €575M (own site) | 4 Nov 2026 | 8 names · Unlock |
| HBM Partners | Fund manager | Zug, Switzerland | Series A, Series B, Growth, Late stage | Biotech, Healthtech, Medtech | Portfolio news, Oct 2026 | $2.8B (own site) | 7 Nov 2026 | 1 name, firm email · Unlock |
| Breakout Ventures | VC firm | San Francisco, CA | Seed | Biotech, AI, Healthtech, Industrial Tech | New deal, Jun 2026 | $112M (SEC Form D, 2021) | 4 Nov 2026 | 6 names, firm email · Unlock |
| Felicis | VC firm | Menlo Park, CA | Seed, Series A | Biotech, AI, Developer Tools, Healthtech | New deal, Oct 2026 | $900M (SEC Form D, 2025) | 5 Nov 2026 | 8 names · Unlock |
| Digitalis Ventures | VC firm | New York, NY | Seed | Biotech, Healthtech, Medtech | Portfolio news, Nov 2026 | $862M (SEC Form ADV) | 5 Nov 2026 | 8 names, firm email · Unlock |
| Artis | VC firm | San Francisco, CA | Biotech, Healthtech, AI, Deep Tech | New fund, Jun 2026 | $300M (SEC Form D, 2022) | 4 Nov 2026 | 5 names · Unlock | |
| Andera Partners | Fund manager | Paris, France | Seed, Series A, Series B, Growth | Biotech, Medtech, Healthtech, Generalist | Portfolio news, Sep 2026 | €6.0B (own site) | 7 Nov 2026 | No contact on file |
| Truffle Capital | VC firm | Paris, France | Biotech, Healthtech, Medtech, Fintech | Portfolio news, Oct 2026 | €500M (own site) | 7 Nov 2026 | 3 names, firm email · Unlock | |
| Cancer Focus Fund | VC firm | Shreveport, LA | Biotech, Healthtech | New fund, May 2026 | $148M (SEC Form ADV) | 5 Nov 2026 | 5 names · Unlock | |
| Fountain Healthcare Partners | VC firm | Dublin, Ireland | Seed | Biotech, Healthtech, Medtech | Portfolio news, Oct 2026 | €425M (own site) | 7 Nov 2026 | 2 names, firm email · Unlock |
| BGF | VC firm | United Kingdom | Seed, Series A, Series B, Growth | Biotech, Healthtech, Edtech, Developer Tools | Portfolio news, Oct 2026 | £3.0B (own site) | 4 Nov 2026 | 8 names · Unlock |
You are seeing 25 of 484. The full list adds 459 more investors and 2,311 named decision-makers.
This list is over 300 rows, so it is delivered inside Global Bundle. One-time payment. No subscription. No account.
Or get the free sample.
Need fewer rows than the whole file? The investor matching tool, opened here for biotech and life sciences, builds a shortlist of up to 300 matching investors for $49, one-time.
How these 484 break down
By region
| Region | On this list | Share |
|---|---|---|
| United States | 302 | 62% |
| United Kingdom | 92 | 19% |
| Europe | 89 | 18% |
Full lists, each with its own row count: Biotech venture capital firms in the US (297)Biotech investors in the UK (92)Biotech investors in Europe (89)
By US state
| US state | On this list | Share |
|---|---|---|
| California | 108 | 22% |
| Massachusetts | 37 | 8% |
| New York | 29 | 6% |
| Texas | 23 | 5% |
| Florida | 15 | 3% |
| Illinois | 7 | 1% |
| Washington | 7 | 1% |
| Connecticut | 7 | 1% |
| Pennsylvania | 5 | 1% |
| Colorado | 5 | 1% |
By European country
| European country | On this list | Share |
|---|---|---|
| France | 18 | 4% |
| Netherlands | 11 | 2% |
| Germany | 11 | 2% |
| Spain | 11 | 2% |
| Sweden | 7 | 1% |
| Austria | 4 | 1% |
| Belgium | 4 | 1% |
| Luxembourg | 4 | 1% |
By stage
Stage is our research. A firm can back more than one stage.
By type
| Type | On this list | Share |
|---|---|---|
| VC firm | 398 | 82% |
| Angel network | 19 | 4% |
| Government or university fund | 18 | 4% |
| Fund manager | 17 | 4% |
| SEIS/EIS fund | 9 | 2% |
| Corporate VC | 7 | 1% |
Method and limits
- Source
- 302 of the 484 rows carry an SEC filing (Form D or Form ADV). 476 of the 484 have a website we checked; the other 8 rest on the filing or register entry alone. Filing date and fund size are SEC data where a filing exists. Stage, sector and check size are our research.
- Inclusion rule
- Organizations that back startups. Individuals, buyout funds and firms we found to be inactive are left out. Sector: the firm states biotech and life sciences as a focus on its own site, or we observed it in the firm's portfolio.
- Order
- Firms with a published profile come first. Activity score out of 100: recency of the latest fund filing or dated deal (40: within 3 months 40, 6 months 30, 12 months 20, 24 months 10), share of the observed portfolio in this sector (30; 15 when the sector is stated only), size of the fund on file on a log scale (20) and completeness of the public record (10). It is a measure of activity and fit, not of quality or returns.
- Last refreshed
- November 2026. Rows on this list were checked between 4 Nov 2026 and 9 Nov 2026.
- Fill rates
- Of 484 rows: stage 385, sector 484, fund size 343, website 476. In the paid file: named decision-makers on 442 rows, firm email on 218, LinkedIn page on 282, check size on 89.
- Corrections
- Email [email protected] or use the update form. We act within 5 working days.
Questions
How many biotech investors are there?
We list 484 as of November 2026. 251 of the 484 have a fund filing or a dated deal in the last 12 months. By region: United States (302), United Kingdom (92) and Europe (89).
Which biotech investors raised a new fund in the last 12 months?
115 of the 484 have a fund filing dated in the last 12 months. The most recent on this list are Hyve Ventures (Nov 2026), Future Ventures (Oct 2026) and Draper Associates (Oct 2026).
What is the typical fund size of biotech investors?
The median fund size on file for this list is $80M, across the 203 firms with a size on an SEC Form D. The fund on file is each firm's main fund, which is not always its newest. The other 281 do not disclose a size there.
Which stage do most biotech investors back?
Of the 385 with a stage on file, seed (300), Series A (153) and pre-seed (148). A firm can back more than one stage, and 99 rows have no stage on file yet.
Where does the data on biotech investors come from and how often is it updated?
302 of the 484 rows have an SEC filing on file (Form D or Form ADV) and 182 were checked on the firm's own website or an official register. Filing date and fund size come from the filing. Stage, sector and check size are our research. Rows on this list were last checked on 9 Nov 2026 at the latest. The whole file is re-verified twice a year.
Can I download the list of biotech investors as a spreadsheet?
Yes. The file holds all 484 rows in Excel and CSV, with 2,311 named decision-makers and 218 firm emails, for $297 one-time as part of Global Bundle. 25 rows are free on this page.
Narrower lists
Seed biotech investors (300)Biotech venture capital firms in the US (297)Series A biotech investors (153)Pre-seed biotech investors (148)Growth-stage biotech investors (109)Biotech investors in the UK (92)Biotech investors in Europe (89)Series B biotech investors (73)
Related lists
CPG investors (165)Consumer investors (512)Ecommerce investors (91)Edtech investors (153)Proptech investors (159)Climate tech investors (660)Deep tech investors (763)Hardware investors (333)Impact investors (131)Food and beverage investors (179)AI investors (1,576)SaaS investors (1,529)Healthtech investors (1,207)Fintech investors (846)Generalist investors (526)Medtech investors (457)B2B investors (438)Energy investors (421)
Not sure this is the right list? Describe your raise in the investor matching tool and get a shortlist. The link opens it set to biotech and life sciences. Guide: how to build an investor list. Markdown version of this page.
Check the quality first
A free sample of 100 investors, every column, with sources and dates.